
## Martin Ullrich

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/528574/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures. Endocrine-Related Cancer, 2022, 29, 285-306.	3.1	12
2	"Clickable―Albumin Binders for Modulating the Tumor Uptake of Targeted Radiopharmaceuticals. Journal of Medicinal Chemistry, 2022, 65, 710-733.	6.4	13
3	HIF2alpha-Associated Pseudohypoxia Promotes Radioresistance in Pheochromocytoma: Insights from 3D Models. Cancers, 2021, 13, 385.	3.7	10
4	Radiolabelled Cyclic Bisarylmercury: High Chemical and inâ€vivo Stability for Theranostics. ChemMedChem, 2021, 16, 2645-2649.	3.2	3
5	Men who stare at bone: multimodal monitoring of bone healing. Biological Chemistry, 2021, 402, 1397-1413.	2.5	3
6	Three-Dimensional Cell Culture Systems in Radiopharmaceutical Cancer Research. Cancers, 2020, 12, 2765.	3.7	32
7	Recent Insights in Barium-131 as a Diagnostic Match for Radium-223: Cyclotron Production, Separation, Radiolabeling, and Imaging. Pharmaceuticals, 2020, 13, 272.	3.8	25
8	Deuteration <i>versus</i> ethylation – strategies to improve the metabolic fate of an <sup>18</sup> F-labeled celecoxib derivative. RSC Advances, 2020, 10, 38601-38611.	3.6	6
9	HIF2α supports pro-metastatic behavior in pheochromocytomas/paragangliomas. Endocrine-Related Cancer, 2020, 27, 625-640.	3.1	33
10	Current Management of Pheochromocytoma/Paraganglioma: A Guide for the Practicing Clinician in the Era of Precision Medicine. Cancers, 2019, 11, 1505.	3.7	120
11	Targeting Cyclooxygenase-2 in Pheochromocytoma and Paraganglioma: Focus on Genetic Background. Cancers, 2019, 11, 743.	3.7	6
12	Impact of Extrinsic and Intrinsic Hypoxia on Catecholamine Biosynthesis in Absence or Presence of Hif2α in Pheochromocytoma Cells. Cancers, 2019, 11, 594.	3.7	24
13	Fluorescent mouse pheochromocytoma spheroids expressing hypoxia-inducible factor 2 alpha: Morphologic and radiopharmacologic characterization. Journal of Cellular Biotechnology, 2019, 5, 135-151.	0.5	8
14	Strain-specific metastatic phenotypes in pheochromocytoma allograft mice. Endocrine-Related Cancer, 2018, 25, 993-1004.	3.1	6
15	Diverse effects of phospholipase A2 receptor expression on LNCaP and PC-3 prostate cancer cell growth in vitro and in vivo. Oncotarget, 2018, 9, 35983-35996.	1.8	9
16	An orthotopic xenograft model for high-risk non-muscle invasive bladder cancer in mice: influence of mouse strain, tumor cell count, dwell time and bladder pretreatment. BMC Cancer, 2017, 17, 790.	2.6	16
17	Multimodal Somatostatin Receptor Theranostics Using [ <sup>64</sup> Cu]Cu-/[ <sup>177</sup> Lu]Lu-DOTA-(Tyr <sup>3</sup> )octreotate and AN-238 in a Mouse Pheochromocytoma Model. Theranostics, 2016, 6, 650-665.	10.0	38
18	In Vivo Fluorescence Imaging and Urinary Monoamines as Surrogate Biomarkers of Disease Progression in a Mouse Model of Pheochromocytoma. Endocrinology, 2014, 155, 4149-4156.	2.8	16